Neurotech International has gained approval to begin a phase I/II clinical trial for their NTI164 proprietary drug on paediatric patients with spastic diplegia cerebral palsy. The unique cannabis-derived formulation will be tested for safety and efficacy in up to 14 non-ambulant patients. The trial intends to enrol patients at the Monash Medical Centre in Victoria.
Read the full story here
Written by: Colin Hay
Published on January 31, 2024 at 07:22PM
Source: Small Caps (opens in new tab)